News | November 07, 2022
Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
The participants discussed the latest developments under ABDM that shall enable true interoperability in the health sector and how effective adoption of ABDM can pave the way towards Universal Health Coverage
A MoU was signed between Ministry of Ayush and Ministry of Tribal Affairs to collaborate in Ayush sector
The symposium was organized to provide an opportunity to highlight the advances of aortic surgery and to discuss the future of aortic aneurysm management.
The MoU will enable both countries to promote research collaboration and building capacities in the field of the Indian Ayurvedic system of traditional medicines
Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
This acquisition will accelerate Medcare's plans to emerge as an international hub for health, beauty, and wellness adding to its existing network of 4 hospitals and over 20 medical centres in the UAE.
The inspection of the facility was conducted from August 16-19, 2022.
Enriched with eight ayurvedic active ingredients like Ashwagandha, Shilajit, Shatavari, and Pippali, Be One works holistically to provide energy, build immunity and enable a healthy body and mind
Subscribe To Our Newsletter & Stay Updated
